Beyond Air, Inc.

Stage 4 · Declining · week 89

As of Oct 22, 2026, Beyond Air is in Stage 4, the downtrend phase, now in week 89 (since Jan 21, 2025). It closed at $2.30, 94.8% below its 52-week high and below its 200-day average, which is falling.

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. More about the company

$2.30

+3.00% today

$2.3M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is XAIR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 26w

S4 30w

S4 91w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 26w → S1 5w → S4 3w → S1 1w → S4 30w → S1 9w → S4 91w current

Total tracked: 166 weeks across 7 stage runs.

XAIR among Medical Devices125th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…125	XAIRBeyond Air, Inc.	Stage 4 · wk 89	5	−23.6%

vs 52W High

-94.8%

$2.10 lo$43.80 hi

94.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 89

1w13w26w

Week 89, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-79.4%

200 DMA: $11.17 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.05x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-23.6%

-55.4%

-79.0%

YTD

-85.4%

-95.3%

Scan Membership

Breakout Watch

Latest: 2022-08-16

6 appearances in last 60 days. First seen: 2019-03-28.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 89 · Vol 0.05x

2026-10-21S4

Wk 89 · Vol 0.10x

2026-10-20S4

Wk 88 · Vol 0.07x

2026-10-19S4

Wk 88 · Vol 0.03x

2026-10-16S4

Wk 88 · Vol 0.05x

2026-10-15S4

Wk 88 · Vol 0.12x

2026-10-14S4

Wk 88 · Vol 0.21x

2026-10-13S4

Wk 87 · Vol 0.13x

2026-10-12S4

Wk 87 · Vol 0.11x

2026-10-09S4

Wk 87 · Vol 0.23x

2026-10-08S4

Wk 87 · Vol 0.36x

2026-10-07S4

Wk 87 · Vol 0.13x

Moving averages & range

50 DMA

$3.47

200 DMA

$11.17

52W High

$43.80

52W Low

$2.10

5D Low

$2.14

Resistance levels (recent highs)

20d High

$2.93

60d High

$6.92

120d High

$11.60

250d High

$43.80

Next resistance

+27.4%

to 20d High

ROE

-519.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.9

Beyond Air: quick answers

What stage is Beyond Air in?

As of Oct 22, 2026, Beyond Air (XAIR) is in Stage 4, the downtrend phase. It entered Stage 4 on Jan 21, 2025 and is in week 89. What the four stages mean

Is Beyond Air in an uptrend?

No. Beyond Air is in a Stage 4 downtrend. It trades 79.4% below its 200-day average, which is falling.

How far is Beyond Air from its 52-week high?

Beyond Air closed at $2.30 on Oct 22, 2026, 94.8% below its 52-week high of $43.80. Its 52-week low is $2.10.

How has Beyond Air performed over the past year?

As of Oct 22, 2026, Beyond Air is down 95.3% over the past year and down 85.4% so far in 2026.

Which sector and industry is Beyond Air in?

Beyond Air is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.